Immuno-Oncology | Specialty

PER Conference Features Expert Views on Lung Cancer Advances

November 7th 2014

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer

November 7th 2014

Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Immunotherapeutic Strategies in Head and Neck Cancer

November 7th 2014

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

Adding GM-CSF to Ipilimumab Improves OS, Lowers Toxicity in Advanced Melanoma

November 5th 2014

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

New Vaccine Formulation Effective in Low-Grade Lymphoma

November 5th 2014

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma

Expert Predicts the Future of Immune Therapies for Lung Cancer

November 1st 2014

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC

November 1st 2014

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLC

October 31st 2014

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

PD-1 Immunotherapies Induce Painless Thyroiditis in Patients With Metastatic Malignancies

October 31st 2014

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

Latest News & Insight: October 27, 2014

October 27th 2014

FDA Grants Breakthrough Therapy Designation to Pembrolizumab for NSCLC

October 27th 2014

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

New Method Explored for Personalized Vaccines for Ovarian Cancer

October 16th 2014

A new method to identify protein mutations in cancer cells may help researchers create a personalized vaccine to treat patients with recurrent ovarian cancer.

Ibrutinib/Nivolumab Combination on Horizon in NHL

October 14th 2014

The combination of the investigational PD-1 immune checkpoint inhibitor nivolumab (Opdivo) and the oral BTK inhibitor ibrutinib (Imbruvica) will be evaluated in a phase I/II trial as a treatment for patients with non-Hodgkin lymphoma.

Petrylak Anticipates Bright Future for PD-L1 Inhibitors in Bladder Cancer

October 9th 2014

Checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1, are showing efficacy in early-phase clinical trials in urothelial bladder cancer, generating the promise of new therapies for a disease that has not had a significant treatment advance in 30 years.

Collaboration Joins Nivolumab With Targeted Therapies in NSCLC

October 7th 2014

A clinical trial collaboration between Novartis and BMS has resulted in the establishment of several novel combination trials involving the PD-1 inhibitor nivolumab and targeted therapies against ALK, c-MET, and T790M for patients with NSCLC.

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

October 6th 2014

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T

October 3rd 2014

In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the implementation of six drugs approved since their previous recommendations were issued in 2007, as well as on older drugs.

Is Breast Cancer Vaccination Coming?

October 1st 2014

Dr. Patrick Borgen Talks About Advances in Breast Cancer

October 1st 2014

Dr. Patrick Borgen Discusses the "Jolie Effect"

October 1st 2014